v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Company’s Segments Including a Reconciliation to Income Before Taxes

The tables below provide information about the Company’s segments and include a reconciliation to income before taxes:

 

                      
   Three Months Ended June 30, 2026    Three Months Ended June 30, 2025  
  Fertility Clinic
Services		   INVOcell
Distribution		    Total    Fertility Clinic
Services		     INVOcell
Distribution		     Total  
                                         
Revenue from external customers  $2,167,785   $7,700    $2,175,485    $ 1,832,094     $ 31,560     $ 1,863,654  
Intersegment revenues   -    2,376     2,376      -       9,000       9,000  
Total segment revenue   2,167,785    10,076     2,177,861      1,832,094       40,560       1,872,654  
                                         
Reconciliation of revenue:                                        
Elimination of intersegment revenue   -    (2,376)    (2,376)     -       (9,000 )     (9,000 )
Total consolidated revenue   2,167,785    7,700     2,175,485      1,832,094       31,560       1,863,654  
                                         
Less:                                        
Cost of revenue   1,357,527    60,147     1,417,675      1,111,129       3,064       1,114,193  
Sales and marketing   19,652    -     19,652      12,263       -       12,263  
General and administrative   457,579    -     457,579      330,774       -       330,774  
Research and development   -    -     -      -       -       -  
Impairment loss   -    -     -      1,397,353       -       1,397,353  
Depreciation and amortization   32,696    2,431     35,127      146,439       2,431       148,870  
Segment profit (loss)  $300,331  $(54,878)   $245,453   $ (1,165,863 )   $ 26,065     $ (1,139,798 )
                                         
Reconciliation to income (loss) from continuing operations before income taxes:                                        
Total segment profit (loss)                   $ 245,453                     $ (1,139,798 )
Other income (loss)              2,411,771                      1,887,479  
Interest expense              (177,227)                     (440,596 )
Unallocated corporate expenses                     (1,535,103 )                     (1,850,290 )
Income (loss) from continuing operations before income taxes                     944,894                       (1,543,205 )
Provision for income taxes                     56,154                       -  
Net income (loss) from continuing operations                     888,740                       (1,543,205 )
Loss on disposition              -                     (1,534,517 )
Loss from discontinued operations             -                     (541,247 )
Net income (loss)                   $ 888,740                     $ (3,618,969 )
                                         
Total assets  $6,238,540   $29,809    $6,268,348    $ 8,679,223     $ 37,102     $ 8,716,325  

 

 

                      
   Six Months Ended June 30, 2026    Six Months Ended June 30, 2025  
  Fertility Clinic
Services		   INVOcell
Distribution		   Total    Fertility Clinic
Services		     INVOcell
Distribution		     Total  
                                        
Revenue from external customers  $4,150,018   $40,692   $4,190,710    $ 3,453,647     $ 47,192     $ 3,500,839  
Intersegment revenues   -    14,376    14,376      -       13,500       13,500  
Total segment revenue   4,150,018    55,068    4,205,086      3,453,647       60,692       3,514,339  
                                        
Reconciliation of revenue:                                       
Elimination of intersegment revenue   -    

(14,376

)   (14,376)     -       (13,500 )     (13,500 )
Total consolidated revenue   4,150,018    

40,692

    4,190,710      3,453,647       47,192       3,500,839  
                                        
Less:                                       
Cost of revenue   2,639,775    65,299    2,705,074      2,171,372       7,048       2,178,420  
Sales and marketing   40,765    -    40,765      25,237       -       25,237  
General and administrative   972,507    -    972,507      637,875       -       637,875  
Research and development     -       -       -       -       -       -  
Impairment loss     -       -       -       1,397,353       -       1,397,353  
Depreciation and amortization   67,516    4,862    72,379      358,895       4,862       363,757  
Segment profit (loss)  $429,455   $(29,469)  $399,986    $ (1,137,084 )   $ 35,282     $ (1,101,802 )
                                        
Reconciliation to income (loss) from continuing operations before income taxes:                                       
Total segment profit (loss)                   $ 399,986                     $ (1,101,802 )
Other income (loss)             (1,356,286)                     1,902,575  
Interest expense             (357,550)                     (440,596 )
Unallocated corporate expenses             (3,280,607)                     (3,087,814 )
Income (loss) from continuing operations before income taxes            (4,594,457)                     (2,727,637 )
Provision for income taxes                     56,154                       -  
Net income (loss) from continuing operations                     (4,650,611 )                     (2,727,637 )
Loss on disposition                     -                       (1,534,517 )
Loss from discontinued operations                     -                       (16,760,401 )
Net income (loss)                   $ (4,650,611 )                   $ (21,022,555 )
                                                 
Total assets  $6,238,540   $29,809   $6,268,348    $ 8,679,223     $ 37,102     $ 8,716,325